New & Notable
Novo, Lilly cut deal with Trump to lower prices of obesity drugs
The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.
— Biopharma Dive
Lilly advances amylin obesity drug eloralintide to phase 3 trials
Eli Lilly is set to begin late-stage clinical trials of its investigational amylin obesity drug next month, after encouraging phase 2 study results.
Improving pharma supply chain visibility with AI technology
AI-driven technology can enhance pharmaceutical supply chains by improving visibility, reducing inefficiencies and predicting shortages for better inventory management.
Top 10 metro areas for manufacturing biologics in 2026
Raleigh ranks as the top U.S. metro for biologics manufacturing investment in 2026, amid skilled labor shortages and shifting federal policies, a new report finds.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Amazon Pharmacy debuts drug-dispensing kiosks at One Medical
Amazon Pharmacy will install drug-dispensing kiosks at select One Medical offices in Los Angeles beginning in December, with plans to expand outside California in 2026.
-
Survey: Pharmacists overwhelmed by volume over value
Most pharmacists feel overwhelmed by competing job demands, which limit patient-centered care for those managing diabetes, a new CCS report finds.
-
Report: Up to 60% of clinical trials don't survive their first year
Between 45% and 60% of new U.S. clinical trial sites shut down within one year, but trial volume and government funding can increase longevity, new research says.
-
How TrumpRx could affect PBMs, specialty pharmacies, biotech
TrumpRx's transparent cash pricing could disrupt PBM rebate models, specialty pharmacy contracts and biotech's commercialization approaches, depending on uptake, experts say.
-
Trump's 100% tariff on branded drug imports spares Big Pharma
Trump's 100% tariff on branded drug imports favors pharma giants building in America, leaving small companies without U.S. manufacturing sites or expansion plans vulnerable.
-
ACIP vaccine votes break with evidence-based policy
The CDC's advisory committee votes to scale back COVID-19 vaccine recommendations for seniors and limit MMRV in children under 4, breaking with decades of evidence-based policy.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.